Asset
Deupsilocin
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06564818 | phase3 | active_not_recruiting | 2024-12-17 | 2026-08-01 | Cybin IRL Limited | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" |
| NCT06793397 | phase3 | recruiting | 2025-12-10 | 2027-03-18 | Cybin IRL Limited | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder |
| NCT05385783 | phase1_2 | completed | 2022-08-02 | 2023-10-16 | Cybin IRL Limited | A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder |
| NCT06605105 | phase3 | enrolling_by_invitation | 2025-07-18 | 2028-03-15 | Cybin IRL Limited | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) |
FDA applications (0)
This company has no applications containing this asset.